Synta Pharma (SNTA) Tops Q3 EPS by 5c

Synta Pharma (NASDAQ: SNTA) reported Q3 EPS of ($0.19), $0.05 better than the analyst estimate of ($0.24).

Based on its current operating levels, the Company expects its cash resources of approximately $119.3 million at September 30, 2014 will be sufficient to fund operations at least into the fourth quarter of 2015. This estimate assumes no additional funding from new partnership agreements, equity financing events or further sales under its ATM, and that the timing and nature of certain activities contemplated for the remainder of 2014 and 2015 will be conducted subject to the availability of sufficient financial resources.

For earnings history and earnings-related data on Synta Pharma (SNTA) click here.

You May Also Be Interested In

• Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
• Lockheed Martin (LMT) PT Raised to $581 at UBS on Revenue Growth Momentum
• Gentex Corporation (GNTX) Tops Q2 EPS by 8c ; Offers Guidance